Enterosgel eliminates harmful substances of exogenous and endogenous origin from the body. Enterosgel modulates beneficial gut microbiota and stimulates mucosal-regeneration.
Enterosgel is approved for the safe and efficient use in treatment of many diseases according the important role of the gastrointestinal tract:
GASTROENTEROLOGY - peptic and duodenal ulcer, irritable bowel syndrome, inflammatory diseases of the small and large intestines, malabsorption syndrome, dysbiosis (also known as dysbacteriosis).
INFECTIOUS DISEASES - viral and bacterial enteritis, enterocolitis, colitis and gastroenteritis of various types (salmonellosis, dysentery, rotaviral gastroenteritis), viral hepatitis.
ALLERGOLOGY - atopic dermatitis/eczema, acute and chronic hives, bronchial asthma, allergic rhinitis, food allergy.
NEPHROLOGY - acute and chronic renal insufficiency, dysmetabolic nephropathy.
TOXICOLOGY - food poisoning, intoxication caused by alcohol, chemicals, aromatic hydrocarbons and heavy metal salts.
OBSTETRICS AND GYNAECOLOGY - pregnancy toxicosis, placental dysfunction, acute and chronic viral, bacterial and fungal vaginal infections.
Volume globular structure of Enterosgel (the frame depicts a pore structure)
Enterosgel has porous structure in the form of solid, spatially formed silicon organic matrix with the specified pore dimensions, which preferentially provide the sorption of middle to high molecule substances.
Microphotograph of Enterosgel taken by electronic microscope
When passing through the digestive tract, the product binds endogenous and exogenous toxic substances of various types, including bacteria and bacterial toxins, antigens, food allergens, medicaments and their by-products as well as alcohol, and eliminates them from the body. The product also binds some metabolic products, including excessive quantities of bilirubin, urea, cholesterol, and lipid complexes as well as metabolites responsible for the development of endogenous toxicosis.
Enterosgel eliminates aromatic hydrocarbons and their derivatives, organic solvents and other industrial poisons as well as incorporated radionuclides from the body.
Enterosgel does not reduce absorption of vitamins and microelements and helps to restore the diminished natural gut microflora. It does not affect the intestinal peristaltic activity .
Enterosgel destroys pathogenic microflora of the gastrointestinal tract and binds the following pathogens: Salmonellas, Shigellae, Klebsiellae and other gram-negative and gram-positive microorganisms and Candida. Enterosgel does not diminish the normal gut microflora. The selective effect of Enterosgel on microflora is due to the fact that, unlike the pathogenic microflora, the normal microflora has high affinity to the intestinal mucosa and thus adheres to it firmly. As a result of electrostatic interaction with Enterosgel, pathogenic microflora is destroyed, while its particles are bound on the sorbent surface.
Enterosgel binds and eliminates viruses (rotaviruses, cytomegaloviruses and others).
Enterosgel also eliminates allergens. Incomplete allergens are totally adsorbed by the porous structure of Enterosgel. Complete allergens are adsorbed by Enterosgel, which provides their elimination from the digestive tract and reduces the potential allergic effects on the body.
USE IN THE MEDICINE
The therapeutic effect of Enterosgel is based upon its ability to adsorb substances damaging mucosal epithelium. This results in the normalization of regenerative processes of the mucosal protective barrier and in the reduced treatment duration for many diseases. First treatment effects depend on the disease, usually being achieved as early as by the first day.
A. Findings in individuals who did not take Enterosgel
Due to impaired microcirculation, mucosal edema develops; sections with large and deep damages of erosive nature are obvious as well as minor multiple bleedings. The ultra-structure of column epithelia and other cells is significantly compromised. Mitotic index decreases by 1.4 times, which evidences reduced proliferation and restoration of damaged epitheliocytes.
B. Findings in individuals who took Enterosgel
The microcirculation stream structure is maintained. Dystrophic alterations are less expressed, desquamation of epitheliocytes is not apparent.
Application of Enterosgel in gastro-duodenal ulcer helps to effectively eliminateHelicobacter pylori. Administration of Enterosgel in intestinal dysbiosis allows to achieve microflora normalization within 10-12 days.
Enterosgel improves subjective general state of the patients, reduces the duration of dyspeptic and painful syndrome as well as fever and normalizes GIT motility.
Use of Enterosgel in inflammatory processes and erosive ulcerations affecting the GIT accelerates regeneration processes in the mucosa.
In case of acute surgical procedures, Enterosgel reduces the level of microbial infection of the abdominal cavity and reduces the intestinal paresis. At the same time the number of post-operative complications is significantly lower.
In patients with intestinal infections, the temperature normalizes on the first day of treatment; bowel movements are normalized by day 2. In viral hepatitis, the positive effects are expressed by improved subjective feeling and better appetite, itching and weakness being reduced; by day 5 to 7 bilirubin and aminotranspherases (ALT/AST) blood levels decrease.
In atopic dermatitis/eczema and other skin allergic diseases the positive effect can be observed as soon as 1-2 days following the start of application of Enterosgel. The average treatment duration is 6-13 days. The inclusion of Enterosgel in the complex therapy for bronchial asthma enables to reduce the severity of the condition or to prevent its deterioration, to prolong the interval between attacks and to normalize immunological factors and respiratory function.
NEPHROLOGY AND UROLOGY
Use of Enterosgel in the complex therapy of therapy of renal insufficiency not only effectively treats, but also other signs of the disease – abdominal, dysuria syndrome and temperature reaction. As a result of treatment with Enterosgel, the toxic and metabolic load on the body is always reduced. Use of Enterosgel contributes to decrease in the acidosis and azotemia values in patients with nephrological conditions and complicated renal insufficiency. When using Enterosgel, creatinine and urea factors drop approx. 1.7–2.2 times by day 10, the hydrogen-carbonate potential of blood is restored, and renal ammonia genesis is improved.
SORPTION DETOXIFICATION PROPERTIES
Enterosgel acts selectively and has a high sorption capacity. It sorbs mostly toxic substances of medium and high molecular mass. It does not cause lack of microtrace elements, calcium, vitamins and other beneficial substances.
Enterosgel destroys pathogenic microorganisms, eliminates exogenous and endogenous toxins produced during the lifetime activity and death of microorganisms. It helps to restore normal microflora.
RESTORATION OF DIGESTIVE TRACT MUCOSA
Enterosgel exhibits cytoprotective effects. It protects the mucosa from chemical and mechanical influence. It restores mucosa, its microcirculation and physiological activity, helping to restore the mucosal immune protection and normalize the level of secretory immunoglobulin A.
Enterosgel is not absorbed in the blood; it is non-toxic, has a gelly-like structure and is chemically inert. Enterosgel does not adhere to mucosal surface and, unlike fine dispersion sorbents, it is not absorbed in the body tissues. Enterosgel is naturally excreted from the body within 24 hours together with the bound substances.
Enterosgel should be given 1-2 hours before or after a meal.
For babies and children under 3, Enterosgel can be used under the advice of a doctor. The single dose for babies under 1 is one third of a teaspoon up to 6 times a day.
Children 3-5 years - 1/3 to 2/3 of a sachet three times a day.
Children 5 yrs+ - take half or one sachet three times a day.
Adults - one sachet three times a day.
Enterosgel is free from preservatives, colours, gluten, fat, sugar, lactose artificial flavours and sweeteners.
THE PRODUCT MAY BE USED BY PREGNANT WOMEN AND CHILDREN.
IT IS AVAILABLE IN THE DRUG STORES AND PHARMACIES WITHOUT PRESCRIPTION.
Volume: 225g tube or sachet 15g